Correlation Between Scopus Biopharma and Oncolytics Biotech

Can any of the company-specific risk be diversified away by investing in both Scopus Biopharma and Oncolytics Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scopus Biopharma and Oncolytics Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Scopus Biopharma and Oncolytics Biotech, you can compare the effects of market volatilities on Scopus Biopharma and Oncolytics Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scopus Biopharma with a short position of Oncolytics Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scopus Biopharma and Oncolytics Biotech.

Diversification Opportunities for Scopus Biopharma and Oncolytics Biotech

0.0

Correlation Coefficient

Scopus Biopharma  Oncolytics Biotech

Pay attention - limited upside

The 3 months correlation between Scopus and Oncolytics is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Scopus Biopharma and Oncolytics Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncolytics Biotech and Scopus Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scopus Biopharma are associated (or correlated) with Oncolytics Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncolytics Biotech has no effect on the direction of Scopus Biopharma i.e., Scopus Biopharma and Oncolytics Biotech go up and down completely randomly.

Pair Corralation between Scopus Biopharma and Oncolytics Biotech

Given the investment horizon of 90 days Scopus Biopharma is expected to under-perform the Oncolytics Biotech. In addition to that, Scopus Biopharma is 3.21 times more volatile than Oncolytics Biotech. It trades about -0.01 of its total potential returns per unit of risk. Oncolytics Biotech is currently generating about -0.01 per unit of volatility. If you would invest  191.00  in Oncolytics Biotech on October 11, 2024 and sell it today you would lose (104.00) from holding Oncolytics Biotech or give up 54.45% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	2.82%
Values	Daily Returns

Scopus Biopharma  vs.  Oncolytics Biotech

Scopus Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Oncolytics Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Scopus Biopharma and Oncolytics Biotech

The main advantage of trading using opposite Scopus Biopharma and Oncolytics Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scopus Biopharma position performs unexpectedly, Oncolytics Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will offset losses from the drop in Oncolytics Biotech's long position.

The idea behind Scopus Biopharma and Oncolytics Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.